Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13. Armata focuses on developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Their pipeline includes candidates for pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, and they collaborate with Merck on synthetic phage candidates targeting an undisclosed infectious disease.

MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.  If you are an institutional or retail investor, and would like to listen to the Company's presentation, click HERE for the conference.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Media Contacts:

At Armata: 
Steve Martin 
Armata Pharmaceuticals, Inc. 
ir@armatapharma.com 
858-800-2492

Investor Relations: 
Joyce Allaire 
LifeSci Advisors, LLC 
jallaire@lifesciadvisors.com 
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-301371143.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Armata Pharmaceuticals participating in the H.C. Wainwright conference?

Armata Pharmaceuticals will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time will Armata Pharmaceuticals' presentation be available?

The presentation by Armata Pharmaceuticals will be available on-demand starting at 7:00 AM ET on September 13, 2021.

What is the focus of Armata Pharmaceuticals?

Armata Pharmaceuticals focuses on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

What pathogens are included in Armata Pharmaceuticals' pipeline?

Armata's pipeline includes clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.

Is Armata Pharmaceuticals collaborating with any other companies?

Yes, Armata Pharmaceuticals is collaborating with Merck to develop proprietary synthetic phage candidates targeting an undisclosed infectious disease agent.